Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Kodak Shares Triple in a Flash on $765 Million Loan from DFC for New Pharmaceutical Unit

Share on Stocktwits


Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation.

JHVEPhoto -

Global technology company Eastman Kodak Co. (KODK:NYSE), which is focused on print, advanced materials and chemicals, today reported that is entering into a financing agreement with the U.S. International Development Finance Corporation (DFC) in order to produce critical pharmaceutical components in the U.S.

The firm indicated that DFC's CEO Adam Boehler intends to issue and sign a letter of interest (LOI) today to provide a loan in the amount of $765 million to Eastman Kodak to fund the launch of Kodak Pharmaceuticals signaling a new moment for the company. According to Eastman Kodak's website, this new business unit has been established in order "to produce up to 25% of active pharmaceutical ingredients used in non-biologic, non-antibacterial, generic pharmaceuticals while supporting 360 direct jobs and an additional 1,200 indirectly."

The report advised that "this project would mark the first use of new authority delegated by President Trump's recent executive order that enables DFC and the U.S. Department of Defense (DOD) to collaborate in support of the domestic response to COVID-19 under the Defense Production Act (DPA)."

DFC's CEO Boehler remarked, "Addressing the unprecedented challenges we face today—and preparing for future crises—requires innovative ideas and partnerships...Today, we are bringing together the significant resources and expertise of the private sector and U.S. Government. We are pleased to support Kodak in this bold new venture. Our collaboration with this iconic American company will promote health and safety at home and around the world."

Eastman Kodak's Executive Chairman Jim Continenza commented, "Kodak is proud to be a part of strengthening America's self-sufficiency in producing the key pharmaceutical ingredients we need to keep our citizens safe...By leveraging our vast infrastructure, deep expertise in chemicals manufacturing, and heritage of innovation and quality, Kodak will play a critical role in the return of a reliable American pharmaceutical supply chain."

Rear Admiral John Polowczyk, White House Supply Chain Task Force Lead, added, "This is about assuring our supply chains now and in the future...Kodak is stepping up to help onshore pharmaceutical production and this DPA action will allow the modernized Strategic National Stockpile to have domestic resiliency. Once Kodak ramps up we will have the ability to tap into that capacity for domestic use."

The report explained that Kodak Pharmaceuticals mission will be to produce essential critical pharmaceutical components that, according to the U.S. Food and Drug Administration (FDA), have recently lapsed into chronic national short supply. It is anticipated that the loan from DCF will accelerate Kodak's time to market by supporting ramp-up costs needed to expand, upgrade and repurpose its facilities in Rochester, N.Y., and St. Paul, Minn.

Kodak is a global technology company headquartered in Rochester, N.Y., that focuses on print and advanced materials & chemicals. The firm has a long well-known history in the film, photography, chemical and copier business and is currently engaged in providing hardware, software, consumables and services to customers in commercial print, packaging, publishing, manufacturing and entertainment.

Eastman Kodak began the day with a market cap of around $114.6 million with approximately 43.7 million shares outstanding and a short interest of about 3.9%. KODK shares opened more than 260% higher today at $9.63 (+$7.01, +267.56%) over yesterday's $2.62 closing price and reached a new 52-week high price this morning of $11.80. The stock has traded today between $7.62 and $11.80 per share and is presently trading at $8.52 (+$5.90, +225.19%).


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe